Descrizione del progetto
Monitoraggio in tempo reale della funzione cardiaca dopo un intervento a cuore aperto
La chirurgia a cuore aperto è un’operazione ad alto rischio in cui il torace viene aperto per esporre il cuore. Questa procedura richiede il monitoraggio continuo della funzione cardiaca allo scopo di individuare potenziali complicazioni; tuttavia, le tecnologie esistenti non riescono a fornire dati precisi e in tempo reale durante e dopo l’intervento chirurgico. Il progetto SAMBAfun, finanziato dall’UE, affronta questa esigenza medica insoddisfatta con un nuovo sensore che può essere incorporato negli elettrocateteri del pacemaker epicardico temporaneo. In poche parole, questa soluzione innovativa permette di misurare la velocità di ciascuna contrazione cardiaca, un fattore fondamentale per il monitoraggio della funzione cardiaca. I dati vengono visualizzati su un monitor e possono avvisare il personale medico di qualsiasi complicazione insorta dopo un intervento chirurgico al cuore.
Obiettivo
In patients undergoing open-heart surgeries, perioperative cardiac monitoring is used to track the functioning of the heart and identify complications. However, myocardial failure and other severe complications can escape detection using current monitoring technologies, given the trade-offs between invasiveness, real time measurements, accessibility and accuracy of data. Given the high-risk profile of these surgeries, failure to timely detect complications leads to increased mortality and morbidity, which in turn results in increased hospitalization costs and lower quality of life for the affected patients.
For effective cardiac monitoring, surgeons need real time data, 24h continuous monitoring during and post-surgery, and an accurate biosignal marker that can be trusted for immediate detection and assessment of cardiac events. No current technology enables this with low invasiveness and risk.
Cardiaccs (SME) and Osypka (SME) will bring to market a patented solution that involves adding a 3-axis accelerometer to a standard epicardial pace lead, which is routinely used for most cardiac surgical patients, to assess cardiac motion and contractility in real time, both during and after surgery – and up to 7 days. Data from CardiSense will appear on a monitor and an alert function will let surgeons and nurses know as soon as a complication is picked-up on the continuously analysed data.
SAMBAfun brings together 2 SMEs with complementary know-how, IPR and value chain positions. Cardiaccs patented the concept, whereas Osypka has 40 years of experience in developing cardiac pace leads. Osypka dominates the German market and has extensive ties to global distributors. Three leading research hospitals (Oslo, Aarhus and Berlin) will demonstrate the latest advances in this device, provide Key Opinion Leader input and contribute with multi-market, highly credible data for regulatory certification and health economic models to support reimbursement applications in all markets.
Campo scientifico
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicinesurgery
- natural scienceschemical sciencesinorganic chemistrypost-transition metals
- medical and health sciencesclinical medicinecardiology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
IA - Innovation actionCoordinatore
0458 Oslo
Norvegia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.